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• Oral rucaparib (600 mg BID) is efﬁcacious in advanced relapsed ovarian carcinoma.
• The objective response rate was 54% in BRCA1/2-mutated ovarian carcinoma.
• Median duration of response was 9.2 months (95% conﬁdence interval, 6.6–11.6).
• Rucaparib had a manageable safety proﬁle in women with advanced ovarian carcinoma.⁎ Corresponding author.
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Available online 4 September 2017Objective. An integrated analysis was undertaken to characterize the antitumor activity and safety proﬁle of
the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcino-
ma (HGOC).
Methods. Eligible patients fromStudy10 (NCT01482715) andARIEL2 (NCT01891344)who received a starting
dose of oral rucaparib 600 mg twice daily (BID) with or without food were included in these analyses. Thempany, Lilly Corporate Center, Indianapolis, IN 46285, USA, but the currentworkwas completed during her timewithMemorial
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
268 A.M. Oza et al. / Gynecologic Oncology 147 (2017) 267–275integrated efﬁcacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or
BRCA2 (BRCA1/2)mutation who received at least two prior chemotherapies and were sensitive, resistant, or re-
fractory to platinum-based chemotherapy. The primary endpoint was investigator-assessed conﬁrmed objective
response rate (ORR). Secondary endpoints included duration of response (DOR) and progression-free survival
(PFS). The integrated safety population included patients with HGOCwho received at least one dose of rucaparib
600 mg BID, irrespective of BRCA1/2mutation status and prior treatments.
Results. In the efﬁcacy population (n= 106), ORR was 53.8% (95% conﬁdence interval [CI], 43.8–63.5); 8.5%
and 45.3% of patients achieved complete and partial responses, respectively. Median DOR was 9.2 months
(95% CI, 6.6–11.6). In the safety population (n = 377), the most frequent treatment-emergent adverse events
(AEs) were nausea, asthenia/fatigue, vomiting, and anemia/hemoglobin decreased. The most common grade
≥3 treatment-emergent AEwas anemia/hemoglobin decreased. Treatment-emergent AEs led to treatment inter-
ruption, dose reduction, and treatment discontinuation in 58.6%, 45.9%, and 9.8% of patients, respectively. No
treatment-related deaths occurred.
Conclusions. Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety
proﬁle.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The 17-member poly(ADP-ribose) polymerase (PARP) superfamily
of nuclear enzymes includes PARP1, PARP2, and PARP3, which are acti-
vated by DNA damage and are key mediators in the repair of single-
strand breaks [1]. Inhibition of PARP1, PARP2, and PARP3 results in col-
lapsed DNA replication forks and development of double-strand breaks
[2,3], which require repair through the BRCA1- and BRCA2-mediated
homologous recombination repair pathway [4–6]. Defects in the homol-
ogous recombination repair pathway—for example, a deleterious BRCA1
or BRCA2 (BRCA1/2) mutation—cause homologous recombination deﬁ-
ciency (HRD) and can selectively sensitize tumors to PARP inhibition
through synthetic lethality [1,7,8]. It is estimated that up to half of
high-grade serous ovarian carcinomas may exhibit HRD, with 18% har-
boring a germline BRCA1/2mutation and 7% a somatic BRCA1/2muta-
tion [9].
Rucaparib (formerly known as CO-338, AG-014447, and PF-
01367338) is an oral, small molecule inhibitor of PARP1, PARP2, and
PARP3 [10–12]. In preclinical studies, increased rucaparib-induced cyto-
toxicity was observed in tumor cell lines with a BRCA1/2mutation, epi-
genetically silenced BRCA1, or other DNA repair deﬁciency [13]. In
mouse xenograft models, rucaparib has been shown to slow growth of
tumors with a deﬁciency in BRCA1/2 [13]. In vitro studies have shown
that rucaparib-induced cytotoxicity may involve inhibition of PARP en-
zymatic activity and increased formation of PARP-DNA complexes
resulting in DNA damage, apoptosis, and cell death [14]. Recently, two
international clinical trials—Study 10 (CO-338-010, NCT01482715)
[15] and ARIEL2 (CO-338-017, NCT01891344) [16]—demonstrated the
antitumor activity of rucaparib in patients with relapsed high-grade
serous or endometrioid epithelial ovarian, fallopian tube, or primary
peritoneal carcinoma (high-grade ovarian carcinoma [HGOC]) and a
deleterious BRCA1/2 mutation (germline in Study 10; germline or so-
matic in ARIEL2).
Here, we report integrated analyses of data from Study 10 and
ARIEL2 that further characterize the antitumor activity and safety of
rucaparib at a starting dose of 600 mg twice daily (BID) in patients
with HGOC and a deleterious germline or somatic BRCA1/2 mutation
who received at least two prior chemotherapies.2. Methods
2.1. Constituent study designs
Study 10 and ARIEL2 enrolled patients aged 18 years or older, with a
life expectancy of at least 3 months, an Eastern Cooperative Oncology
Group Performance Status (ECOG PS) of 0 or 1, and adequate organ
function. All patients provided written informed consent.Study 10 is a three-part, open-label, phase I/II study of oral rucaparib
given until disease progression or unacceptable toxicity. Part 1was con-
ducted in patients with a relapsed advanced solid tumor (a known
BRCA1/2 mutation was not required) and established rucaparib
600mg BID as the recommended dose for phase II and phase III evalua-
tion. Part 1 also established that rucaparib could be taken with or with-
out food. Part 2A enrolled patients with platinum-sensitive (disease
progression ≥6 months after last dose of platinum) relapsed HGOC
and a germline BRCA1/2mutation (detected by local testing) who had
received two to four prior therapies. The primary endpoint in Part 2A
was conﬁrmed investigator-assessed objective response rate (ORR)
per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST);
secondary endpoints included duration of response (DOR), progres-
sion-free survival (PFS), and safety. Part 2B of the study enrolled pa-
tients with platinum-sensitive, -resistant, or -refractory HGOC with a
germline or somatic BRCA1/2 mutation who received three to four
prior chemotherapy regimens. The primary endpoint in Part 2B is inves-
tigator-assessed ORR. No patients were enrolled in Study 10 Part 2B
prior to the enrollment cutoff date of October 1, 2015; thus no data for
patients enrolled in Part 2B are included in this analysis. Part 3 enrolled
patients with a relapsed solid tumor and a germline or somatic BRCA1/2
mutation (detected by local or central testing) for assessment of the
pharmacokinetic and safety proﬁles of a higher dose tablet of rucaparib.
ARIEL2 is a two-part, phase II, open-label study of oral rucaparib
600 mg BID given until disease progression, unacceptable toxicity, or
death in patients with relapsed HGOC. A known BRCA1/2 mutation
was not required in ARIEL2; tumor BRCA1/2 statuswas determined cen-
trally using the Foundation Medicine FoundationFocus™ CDxBRCA assay
(Foundation Medicine, Inc., Cambridge, MA, USA) [17] and germline
testing of DNA extracted from blood was performed using BROCA-ho-
mologous recombination sequencing assay (University of Washington,
Seattle, WA, USA) [16,18]. A somatic BRCA1/2mutation was deﬁned as
a mutation detected in the DNA extracted from tumor tissue but not
from blood. For all mutations, biallelic inactivation of BRCA1/2 genes
was demonstrated through germline or somatic BRCA1/2 mutation at
one allele and loss of heterozygosity of the other allele. Part 1 enrolled
patients with platinum-sensitive, relapsed HGOC who had received at
least oneprior platinum-based regimen andhad platinum-sensitive dis-
ease. Part 2 is enrolling patients with relapsed HGOC who had received
at least three, but not more than four, prior chemotherapies and had a
treatment-free interval of N6months followingﬁrst-line chemotherapy.
Patients in Part 2 could be platinum-sensitive (disease progression
≥6months after last platinum), platinum-resistant (disease progression
b6 months after last platinum, with best response other than progres-
sive disease [PD]), or platinum-refractory (best response of PD on last
platinum with progression-free interval [PFI] b2 months).
In both trials, treatment interruptions and dose reductionswere per-
mitted: for patients who received a 600 mg BID starting dose of
Table 1
Baseline patient characteristics and prior chemotherapy in the integrated efﬁcacy and
safety populations.
Integrated efﬁcacy
population (n= 106)
Integrated safety
population (n= 377)
Median age (range), years 59 (33–84) 62 (31–86)
Race, n (%)
White 83 (78.3) 302 (80.1)
Asian 7 (6.6) 22 (5.8)
Black or African American 4 (3.8) 8 (2.1)
Other 2 (1.9) 7 (1.9)
Missing 10 (9.4) 38 (10.1)
ECOG PS, n (%)
0 65 (61.3) 233 (61.8)
1 41 (38.7) 144 (38.2)
Cancer type, n (%)
Epithelial ovarian carcinoma 91 (85.8) 305 (80.9)
Fallopian tube carcinoma 9 (8.5) 33 (8.8)
Primary peritoneal
carcinoma
6 (5.7) 39 (10.3)
Histological classiﬁcation, n
(%)
Serous 97 (91.5) 355 (94.2)
Mixeda 5 (4.7) 11 (2.9)
Endometrioid 3 (2.8) 9 (2.4)
Clear cell carcinoma 1 (0.9) 1 (0.3)
Unknown 0 1 (0.3)
Median time since cancer
diagnosis (range), months
51.7 (6.3–196.6) 42.7 (6.3–196.6)
BRCA1/2 mutation type, n (%)
Germline 88 (83.0) 108 (28.6)
Somatic 18 (17.0) 28 (7.4)
Mutation of uncertain origin 0 7 (1.9)
No mutation (BRCA
wild-type)
0 234 (62.1)
BRCA gene mutation, n (%)
BRCA1 67 (63.2) 89 (23.6)
BRCA2 39 (36.8) 54 (14.3)
No mutation 0 234 (62.1)
Median number of prior
chemotherapies (range)
3 (2–6) 2 (1–7)
1 prior chemotherapy, n (%) 0 127 (33.7)
2 prior chemotherapies, n
(%)
41 (38.7) 85 (22.5)
≥3 prior chemotherapies, n
(%)
65 (61.3) 165 (43.8)
Median number of
platinum-based therapies
(range)
2 (2–5) 2 (1–5)
1 prior platinum-based
therapy, n (%)
0 131 (34.7)
2 prior platinum-based
therapies, n (%)
60 (56.6) 144 (38.2)
≥3 prior platinum-based
therapies, n (%)
46 (43.4) 102 (27.1)
PFI from last platinum-based
therapy, n (%)
N12 months 23 (21.7) 129 (34.2)
6–12 months 56 (52.8) 152 (40.3)
b6 months 27 (25.5) 90 (23.9)
Missing 0 6 (1.6)
Platinum response to last
therapy, n (%)
Sensitiveb 79 (74.5) 283 (75.1)
Resistantc 20 (18.9) 67 (17.8)
Refractoryd 7 (6.6) 26 (6.9)
Unknown 0 1 (0.3)
ECOG PS, Eastern Cooperative Group Oncology Performance Status; PFI, progression-free
interval.
a Additional details provided in Table S1, Supplementary Data.
b Platinum sensitivity represents disease progression ≥6 months after last platinum.
c Platinum resistance represents disease progression b6 months after last platinum,
with best response other than progressive disease.
d Platinum-refractory patients had a best response of progressive disease on last plati-
num, with PFI b2 months.
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steps were in 120 mg BID increments (e.g., 600 mg BID to 480 mg
BID) down to 240mg BID. In Study 10 Part 3 and ARIEL2 Part 2, dose re-
duction steps were in 100 mg BID increments down to 300 mg BID.
In both trials, patients with mild hepatic impairment (deﬁned as al-
anine/aspartate aminotransferase [ALT/AST] N upper limit of normal
[ULN]with total bilirubin ≤ULNor any ALT/AST level with total bilirubin
N1.0–1.5 × ULN) were permitted to enroll. Patients with moderate (de-
ﬁned as ALT/AST level and total bilirubin N1.5–3 × ULN) or severe (de-
ﬁned as any ALT/AST level and total bilirubin N3 × ULN) hepatic
impairment were excluded.
2.2. Integrated analysis datasets
The integrated efﬁcacy population included patients from Study 10
(Part 2A only) and ARIEL2 (Parts 1 and 2) who met the following eligi-
bility criteria: diagnosis of ovarian carcinoma (inclusive of primary peri-
toneal and fallopian tube carcinoma); received at least one dose of
rucaparib 600mg; received at least two prior chemotherapies, including
at least two platinum-based therapies; and had a deleterious BRCA1/2
mutation (germline BRCA1/2mutation in Study 10; germline or somatic
BRCA1/2mutation in ARIEL2) (Fig. S1, Supplementary Data).
To enable a comprehensive evaluation of rucaparib safety in patients
with ovarian carcinoma, the integrated safety population included
Study 10 (Parts 1, 2A, and 3) and ARIEL2 (Parts 1 and 2) patients with
a diagnosis of ovarian carcinoma (inclusive of primary peritoneal and
fallopian tube carcinoma) who had taken at least one dose of rucaparib
600mg. Patients were included in the integrated safety population irre-
spective of their BRCA1/2mutation status and number or type of prior
therapies.
For both integrated analyses, the study enrollment cutoff date was
October 1, 2015. The efﬁcacy analysis visit cutoff dates were November
30, 2015 (Study 10 Part 2A), and February 29, 2016 (ARIEL2 Parts 1 and
2). The safety analysis visit cutoff dates were March 31, 2016 (Study 10
Parts 1, 2A, and 3) and April 29, 2016 (ARIEL2 Parts 1 and 2).
2.3. Integrated efﬁcacy analysis outcomes
The primary outcome of interest in the integrated efﬁcacy analysis
was investigator-assessed ORR per RECIST, deﬁned as the proportion
of patientswith a conﬁrmed complete response (CR) or partial response
(PR) on subsequent tumor assessment at least 28 days after the ﬁrst re-
sponse documentation [19].
In Study 10 and ARIEL2, tumor assessments included clinical exam-
ination and appropriate imaging techniques (preferably computed to-
mography scans of chest, abdomen, and pelvis, with slice thickness
per RECIST); other methods (e.g., magnetic resonance imaging) were
utilized if required. In Study 10, assessments were performed at screen-
ing, at the end of every 6 weeks (±7 days) of treatment until week 18,
and every 9weeks (±7 days) thereafter; if an initial CR or PRwas noted
after week 18, conﬁrmatory scans were performed 4 to 6weeks later. In
ARIEL2, assessments were performed at screening and at the end of
every 8 weeks (±4 days) of treatment, although for patients who had
been on study for at least 18 months, the frequency of tumor assess-
ments could be reduced to every 16 weeks (±2 weeks).
Integrated subgroup analyses for ORR included the number of prior
chemotherapies (2 or ≥3), the number of prior platinum-based thera-
pies (2), PFI from the last platinum-based therapy (N12, 6–12, or b-
6 months), platinum response status following the last platinum-
based therapy (sensitive, resistant, or refractory), age (b65 or
≥65 years old), race (white, non-white, or unknown), ECOG PS (0 or
1), and treatment location (US or non-US).
Secondary endpoints included investigator-assessed ORR per Gyne-
cological Cancer InterGroup (GCIG) combined RECIST and cancer anti-
gen 125 (CA-125) criteria, investigator-assessed best response in the
sum of target lesions, DOR, and PFS. An independent radiology review
Table 2
Investigator-assessed conﬁrmed objective response rate and duration of response (per
RECIST) in the integrated efﬁcacy population and individual study parts.
Study 10 (n
= 42)
ARIEL2 (n
= 64)
Pooled efﬁcacy
population (n= 106)
Objective response rate, n
(%) [95% CI]a
25 (59.5)
[43.3–74.4]
32 (50.0)
[37.2–62.8]
57 (53.8)
[43.8–63.5]
Best overall response, n
(%)
Complete response 4 (9.5) 5 (7.8) 9 (8.5)
Partial response 21 (50.0) 27 (42.2) 48 (45.3)
Stable disease 12 (28.6) 24 (37.5) 36 (34.0)
Progressive disease 2 (4.8) 7 (10.9) 9 (8.5)
Not evaluable 3 (7.1) 1 (1.6) 4 (3.8)
CI, conﬁdence interval; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1.
a Objective response represents investigator-assessed conﬁrmed complete response
+ partial response, per RECIST.
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target lesions was the percentage change from baseline in the sum of
the diameter(s) of all target lesions. DOR was analyzed using Kaplan-
Meier methodology; data were censored at the date of the last
postbaseline scan for patients who had an ongoing response at the
time of the visit cutoff. PFSwas also analyzed using Kaplan-Meiermeth-
odology, with data censored at the last visit for patients without
documentedprogressionor death. Due to the lack of a comparator treat-
ment arm, no statistical testing was performed and no multiplicity ad-
justment was required. Analyses are presented descriptively.2.4. Integrated safety analysis outcomes
In both trials, safety assessments included adverse event (AE) mon-
itoring and laboratory investigations. Verbatim AE terms were coded
using the Medical Dictionary for Drug Regulatory Activities version
18.1 [20]. Severities of the AE and laboratory abnormalities were classi-
ﬁed according to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.03 [9]. Grade 3/4 AEs wereFig. 1. Investigator-assessed conﬁrmed ORR per RECIST in the integrated efﬁcacy populatio
Performance Status; ORR, objective response rate; PFI, progression-free interval to last platinu
United States.managed with dose modiﬁcation (treatment interruption and/or dose
reduction) or treatment discontinuation.
Safety outcomes of interest in the integrated analysis were treat-
ment-emergent AEs of all grades, grade ≥3 treatment-emergent AEs, se-
rious AEs, treatment-related AEs, AEs leading to dose modiﬁcation
(treatment interruption and/or dose reduction), AEs leading to treat-
ment discontinuation, and AEs leading to death.3. Results
3.1. Integrated efﬁcacy population
The integrated efﬁcacy population included 106 patients from Study
10 Part 2A (n=42) and ARIEL2 Parts 1 and 2 (n=64) (Fig. S1, Supple-
mentary Data).
At baseline in the integrated efﬁcacy population, median age was 59
(range, 33–84) years, all patients had an ECOG PS of 0 or 1 (61.3% and
38.7%, respectively), and 85.8% of patients had epithelial ovarian, 8.5%
had fallopian tube, and 5.7% had primary peritoneal carcinoma (Table
1). All patients had a deleterious BRCA1/2mutation; 83.0% of patients
had a germline BRCA1/2mutation, and 17.0% had a BRCA1/2mutation
detected in tumor tissue but not in whole blood (i.e., somatic BRCA1/2
mutation). The majority of patients had a BRCA1 mutation (63.2%);
the remainder had a BRCA2 mutation (36.8%). Of the nine patients
with nonserous ovarian cancer, ﬁve had a BRCA1 mutation (2 with
mixed, 2 with endometrioid, and 1 with clear cell histology), and four
had a BRCA2mutation (3 with mixed and 1 with endometrioid histolo-
gy). BRCA1/2mutation status in tumor was centrally conﬁrmed retro-
spectively in 96.0% (64/67) of the patients for whom a tumor tissue
sample was available for analysis with the companion diagnostic
FoundationFocus CDxBRCA assay. All patients received at least two prior
lines of chemotherapy (median, 3; range, 2–6), inclusive of platinum-
based therapies, 61.3% received three or more prior lines of chemother-
apy, and 74.5% exhibited sensitivity to their last platinum-based thera-
py. The median PFI from the last platinum-based therapy was 8.0
(range,−0.7–116.4) months.n, by subgroup. CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group
m-based therapy; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1; US,
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In the integrated efﬁcacy population, the investigator-assessed
conﬁrmed ORR per RECIST was 53.8% (95% conﬁdence interval [CI],
43.8–63.5) (Table 2; Fig. 1). Best overall investigator-assessed con-
ﬁrmed responses of CR and PR were achieved in 8.5% and 45.3% of pa-
tients, respectively; 34.0% of patients had stable disease and 8.5% had
PD. The majority of patients (84.9%) had a decrease from baseline in
the sum of the diameter of target lesions, with most decreases being
≥30% (Fig. 2A). For the secondary endpoint of investigator-assessed
conﬁrmed response per combined RECIST and GCIG CA-125 criteria,
the ORR was 70.8% (95% CI, 61.1–79.2).
Findings from prespeciﬁed, exploratory subgroup ORR analyses in
the integrated efﬁcacy population are summarized in Fig. 1. The ORR
was similar among patients in several of the subgroups, including pa-
tients with a germline or somatic BRCA1/2mutation and patients with
a BRCA1 or BRCA2mutation. TheORRwashigher in patientswhohad re-
ceived exactly two prior lines of chemotherapy (inclusive of platinum-
based chemotherapy) than in patients who received three or more
prior lines of chemotherapy. Patients with a PFI from their last plati-
num-based therapy N12 months had a higher ORR than those with a
PFI of 6 to 12 months or b6 months. Patients who were sensitive toFig. 2. (A) Best percentage change from baseline for target lesions and (B) duration of respon
response for target lesions represents the largest percentage decrease from baseline in the su
with zero change from baseline are shown as 0.5% for visual clarity; the upper dotted line in
diameter of the target lesions, whereas the lower dotted line indicates the threshold for partia
bars represent patients with a germline BRCA1/2 mutation; striped bars represent patients
methodology; data were censored at the date of the last postbaseline scan for patients who
Response Evaluation Criteria In Solid Tumors version 1.1. *Three patients did not have a postbatheir most recently administered platinum regimen had a higher ORR
than those who were resistant or refractory to their most recent plati-
num regimen.
In the integrated efﬁcacy population, themedian duration of investi-
gator-assessed conﬁrmed response was 9.2 (range, 1.7–19.8; 95% CI,
6.6–11.6) months (Fig. 2B); 47.4% of patients with a response had not
progressed at the time of the visit cutoff. Investigator-assessed PFS in
the integrated efﬁcacy population was 10.0 (range, 0.0–22.1; 95% CI,
7.3–12.5) months (Fig. S2A, Supplementary Data); 47.2% of patients
had not progressed at the time of the visit cutoff. The PFS rate at 6 and
12 months was 79.0% and 41.0%, respectively (Fig. S2A, Supplementary
Data). Investigator-assessed PFS was 11.1 (95% CI, 7.3–12.8) months in
patients who were sensitive to their most recently administered
platinum regimen (n= 79), and 7.4 (95% CI, 5.5–not reached) months
and 5.3 (95% CI, 1.7–not reached) months in those who were resistant
(n= 20) or refractory (n= 7) to their most recent platinum regimen,
respectively (Fig. S2B, Supplementary Data).
According to the independent radiology review, the conﬁrmed ORR
per RECIST in the integrated efﬁcacy population was 41.5% (95% CI,
32.0–51.5); 4.7% of patients achieved a CR and 36.8% achieved a PR.
The median DOR according to the independent radiology review was
6.7 (range, 1.7–13.3; 95% CI, 5.5–11.1) months.se, each by investigator assessment per RECIST in the integrated efﬁcacy population. Best
m of the longest diameter of target lesions; each bar represents a single patient; patients
dicates the threshold for progressive disease, a 20% increase in the sum of the longest
l response, a 30% decrease in the sum of the longest diameter of the target lesions; solid
with a somatic BRCA1/2 mutation. Duration of response was analyzed by Kaplan-Meier
had an ongoing response at the time of the visit cutoff. CI, conﬁdence interval; RECIST,
seline scan.
Table 3
Safety summary: all patients with ovarian carcinoma who received ≥1 dose of rucaparib
600 mg BID.
Summary of AEs Integrated ovarian carcinoma
safety population (n= 377)a
n (%)
AE leading to dose modiﬁcation (dose
reduction or treatment interruption)
233 (61.8)
AE leading to dose reduction 173 (45.9)
AE leading to treatment interruption 221 (58.6)
AE leading to treatment discontinuationb 37 (9.8)
AE leading to death 9 (2.4)
Malignant neoplasm progression 8 (2.1)
Nonprogression AE leading to death 1 (0.3)
Individual AE occurring in ≥20% of patientsc Any grade, n (%) Grade 3/4, n (%)
Nausea 290 (76.9) 19 (5.0)
Asthenia/fatigued 289 (76.7) 41 (10.9)
Vomiting 174 (46.2) 15 (4.0)
Anemia/hemoglobin decreasedd 165 (43.8) 94 (24.9)
ALT/AST increasedd 156 (41.4) 41 (10.9)
Constipation 150 (39.8) 6 (1.6)
Decreased appetite 148 (39.3) 10 (2.7)
Dysgeusia 148 (39.3) 1 (0.3)
Diarrhea 130 (34.5) 9 (2.4)
Abdominal pain 119 (31.6) 13 (3.4)
Dyspnea 81 (21.5) 2 (0.5)
Thrombocytopenia/platelet count decreasedd 79 (21.0) 17 (4.5)
Blood creatinine increased 79 (21.0) 2 (0.5)
Laboratory abnormalitiese Any grade, n (%) Grade 3/4, n (%)
Increase in creatinine 347 (92.0) 5 (1.3)
Increase in ALT 279 (74.0) 47 (12.5)
Increase in AST 276 (73.2) 17 (4.5)
Decrease in hemoglobin 251 (66.6) 88 (23.3)
Decrease in lymphocytes 168 (44.6) 26 (6.9)
Increase in cholesterol 150 (39.8) 9 (2.4)
Decrease in platelets 147 (39.0) 23 (6.1)
Decrease in neutrophils 132 (35.0) 37 (9.8)
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a All data are from patients with ≥1 event.
b Excludes patients who discontinued because of disease progression.
c Other grade 3/4 AEs occurring in ≥3% of patients were: neutropenia/neutrophil count
decreased (8.2%); malignant neoplasm progression (5.0%); and small intestinal obstruc-
tion (3.7%).
d To ensure full representation of similar AEs, certain terms were combined.
e For laboratory abnormalities, “Any grade” represents any worsening shift from base-
line, and “grade 3/4” represents a maximum shift to grade 3/4.
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The integrated ovarian carcinoma safety population included 377
patients from Study 10 Parts 1, 2A, and 3 (n= 62), and ARIEL2 Parts 1
and 2 (n = 315) (Fig. S1, Supplementary Data). The median duration
of rucaparib treatment in the integrated safety population was 5.5
(range, 0.1–28.0) months.
At baseline in the integrated safety population, median age was 62
(range, 31–86) years. All patients had an ECOG PS of 0 or 1 (61.8% and
38.2%, respectively); 80.9% of patients had epithelial ovarian carcinoma
(Table 1). Approximately one-third of patients (37.9%) had a deleterious
BRCA1/2 mutation (germline or somatic). All patients had received at
least one prior line of chemotherapy; 43.8% had received three or
more prior lines of chemotherapy (inclusive of platinum-based thera-
pies), and 27.1% had received three or more platinum-based therapies.
3.4. Integrated safety ﬁndings
All patients in the integrated safety population had at least one treat-
ment-emergent AE, and 60.7% had a grade ≥3 treatment-emergent AE.
The most frequently reported treatment-emergent AEs were nausea
(76.9%), asthenia/fatigue (76.7%), vomiting (46.2%), anemia/hemoglo-
bin decreased (43.8%), and ALT/AST increased (41.4%) (Table 3).Median
time to onset of anemia (preferred term only) was approximately
54 days. Common grade ≥3 treatment-emergent AEs included ane-
mia/hemoglobin decreased (24.9%), asthenia/fatigue (10.9%), and ALT/
AST increased (10.9%).Myelodysplastic syndrome (MDS) and acutemy-
eloid leukemia (AML) were reported as an AE in one patient each after
57 and 539 days of rucaparib treatment, respectively; both patients
had received at least 12 cycles of prior platinum-based therapy, and nei-
ther patient had a BRCA1/2mutation. Immediately following the MDS
and AML diagnosis, rucaparib treatment was discontinued.
The most frequently observed lab abnormalities were increase in
creatinine (any worsening in grade, 92.0%; shift to grade 3/4, 1.3%), in-
crease in ALT (any worsening in grade, 74.0%; shift to grade 3/4,
12.5%), increase in AST (any worsening in grade, 73.2%; shift to grade
3/4, 4.5%), and decrease in hemoglobin (any worsening in grade,
66.6%; shift to grade 3/4, 23.3%) (Table 3). Creatinine increaseswere ob-
served within the ﬁrst few weeks of rucaparib treatment and then sta-
bilized with continued rucaparib treatment (Fig. 3A).
Elevations in ALT/ASTwere also observedwithin the ﬁrst fewweeks
of rucaparib treatment (Fig. 3B). These elevations were mostly asymp-
tomatic, reversible, and were rarely associated with increases in biliru-
bin (Fig. 3C); the elevations generally normalized over time with
continued treatment and only resulted in treatment discontinuation in
one patient (0.3%). At study entry, 32 patients had mild hepatic impair-
ment, and 345 patients had no hepatic impairment. Therewas no differ-
ence in the incidence of all-grade treatment-emergent AEs between
patients with or without mild hepatic impairment (100% in each
group). The incidence of grade 3 or higher treatment-emergent AEs
was reported in 59.4% and 60.9% of patientswith orwithoutmild hepat-
ic impairment, respectively.
Treatment-emergent AEs led to treatment interruption in 58.6% of
patients and dose reduction in 45.9% of patients (Table 3). AEsmost fre-
quently leading to dose modiﬁcation (dose reduction or treatment in-
terruption) included anemia/hemoglobin decreased (21.5%), asthenia/
fatigue (20.7%), nausea (18.0%), vomiting (11.9%), ALT/AST increased
(10.3%), and thrombocytopenia/platelets decreased (9.8%). Treatment-
emergent AEs led to treatment discontinuation in 9.8% of patients (ex-
cluding those who discontinued because of disease progression)
(Table 3). Treatment-emergent AEs leading to treatment discontinua-
tion in ﬁve or more patients included asthenia/fatigue (2.4%) and nau-
sea (1.3%).
An AE with an outcome of death occurred in 2.4% of patients (9
deaths). Of those deaths, 8 were associated with malignant neoplasm
progression. The ninth patient died from sepsis and clinical progression,which was assessed by the investigator to be unrelated to rucaparib
treatment.
4. Discussion
Results from this integrated analysis demonstrate that oral rucaparib
(600 mg BID) has antitumor activity in patients with HGOC and a dele-
terious germline or somatic BRCA1/2mutation who have received two
or more prior chemotherapies. More than half (53.8%) of patients with
HGOC achieved a CR (8.5%) or PR (45.3%). Responses to rucaparib
were durable, with amedian DOR of 9.2months. Based on these results,
single-agent rucaparib received accelerated approval from the United
States Food and Drug Administration in December 2016 for treatment
of women with deleterious BRCA mutation (germline and/or somatic)
associated advanced ovarian cancer who have been treated with two
or more chemotherapies.
Results of the integrated efﬁcacy analysis also demonstrated antitu-
mor activity in subgroups within the efﬁcacy population. Notably, the
ORR was higher in patients who had received only two prior chemo-
therapies (68.3%) than in those who received three or more prior che-
motherapies (44.6%). The ORR was also higher in platinum-sensitive
patients (65.8%) than in platinum-resistant (25.0%) or platinum-
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peared to derive some measure of clinical beneﬁt as demonstrated by
themedian PFS in each subgroup (11.1, 7.4, and 5.3months, respective-
ly). Additionally, this analysis showed that theORRwas similar between
patients with a germline or somatic BRCA1/2mutation and between pa-
tients with a BRCA1 or BRCA2mutation.Fig. 3.Baseline and on-treatment values for (A) creatinine, (B) ALT/AST, (C) bilirubin, and (D) pl
of normal. ALT, alanine aminotransferase; AST, aspartate aminotransferase; SE, standard error.Other PARP inhibitors, including olaparib, veliparib, and niraparib,
have also been investigated in ovarian carcinoma in the treatment set-
ting. In Study 42, olaparib had an ORR of 33.6%, a median DOR of
7.9 months, and median PFS of 6.7 months in patients with advanced
ovarian carcinoma and a germline BRCA1/2mutation who had received
at least three prior chemotherapies [21]. In a phase II trial, treatmentatelets in the integrated safety population. Dashed lines indicate the upper and lower limits
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patients with recurrent ovarian carcinoma and a germline BRCA1/2mu-
tation who had received up to three prior chemotherapies [22].
Niraparib is currently being evaluated in the treatment setting for pa-
tientswith ovarian cancerwhohave received three to four prior chemo-
therapies (QUADRA; NCT02354586). At this time, we are not aware of
any head-to-head trials of PARP inhibitors in the setting of HGOC;
thus, direct comparisons cannot be made between agents in this class.
If indirect comparisons were to be made, they would likely be con-
founded by differences in patient populations, tumor histologies and/
or subtype, trial design, and study execution. Nevertheless, a common
observation within clinical trials that have investigated PARP inhibitors
is that patients with platinum-sensitive disease are more likely to re-
spond to PARP inhibitors than patients with platinum-resistant or plat-
inum-refractory disease [23,24]. In the United States, olaparib is
approved as a monotherapy in the treatment setting for patients with
HGOC and a germline BRCA1/2 mutation who have received three or
more prior chemotherapies. In the European Union, olaparib is ap-
proved as monotherapy for the maintenance treatment of patients
with platinum-sensitive, relapsed, BRCA-mutated (germline and/or so-
matic), high-grade serous epithelial ovarian, fallopian tube, or primary
peritoneal cancer who are in remission (CR or PR) to platinum-based
therapy. Niraparib and olaparib are approved in the United States as
monotherapy for maintenance treatment of patients with recurrent ep-
ithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
complete or partial response to platinum-based chemotherapy.
The integrated safety analysis in patients with ovarian carcinoma
demonstrated that rucaparib has amanageable safety proﬁle. In the set-
ting of these two trials, treatment-emergent AEs and lab abnormalities
were managed with treatment interruption, treatment modiﬁcation,
and/or supportive care such as antiemetic medications for nausea or
vomiting (e.g., 5-HT antagonist and a corticosteroid with or without a
NK1 antagonist or palonosetron with dexamethasone) or red blood
cell transfusions for anemia. Treatment discontinuations due to treat-
ment-emergent AEs not related to disease progression were infrequent
(9.8%). Furthermore, gastrointestinal side effects, asthenia/fatigue, and
myelosuppression are consistent with toxicities already observed with
the PARP inhibitor class of agents [21,22,24,25].
Creatinine increases observed with rucaparib were predominantly
grade 1 or 2 andusually occurredwithin theﬁrst fewweeks of rucaparib
treatment and then stabilized. In the setting of these two trials, mild to
moderate elevations in serum creatinine did not require dose modiﬁca-
tion. In vitro studies have shown that rucaparib potently inhibitsMATE1
and MATE2-K and moderately inhibits OCT-1 [26], renal transporters
that play a role in the secretion of creatinine into the proximal tubule
and subsequent apical efﬂux into urine. Olaparib has been shown to in-
hibit MATE1, MATE2-K, and OCT2 in vitro [27]; veliparib also inhibits
MATE1 and MATE2-K in vitro [28]. Increases in creatinine have also
been observed following the use of olaparib in the setting of advanced
ovarian cancer [29]. Thus, increases in blood creatinine observed follow-
ing rucaparib treatment may be a PARP inhibitor class effect.
Observed ALT/AST elevations were transient and normalized over
time with continued rucaparib treatment. Although no differences
were observed in the rate of AEs in patients with orwithoutmild hepat-
ic impairment, a clinical pharmacokinetic studywill be completed tode-
termine the most appropriate starting dose for rucaparib in patients
with moderate hepatic impairment.
A limitation of this integrated analysis is that these data were gener-
ated from two open-label, single-arm, nonrandomized phase II trials
with unique study designs and overlapping patient populations. Fur-
thermore, randomized data are not yet available for rucaparib in the
treatment setting; however, a phase III trial is underway to further eval-
uate rucaparib versus standard-of-care chemotherapy in patients with
relapsed ovarian carcinoma with a BRCA1/2mutation in the treatment
setting (ARIEL4; NCT02855944). Rucaparib is also being compared
with placebo in patients with ovarian carcinoma in a phase III trial inthe maintenance treatment setting (ARIEL3; NCT01968213). Both
phase III trials will explore the use of biomarkers, including BRCA1/2
mutations, for predicting response to rucaparib treatment in patients
with HGOC.
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